Drug intelligence / Profile preview

MAX-425

Development stage: Preclinical
Lead developer: Maxona Pharmaceuticals

Overview

MAX-425 is an investigational drug candidate being developed by Maxona Pharmaceuticals for the treatment of chronic pruritus of unknown origin (CPUO). As of 2026, the drug is in the preclinical stage of development, with the company conducting formulation optimization, target identification, and longer-term 6-to-9-month preclinical toxicology studies. Maxona Pharmaceuticals targets initiating Phase 2 clinical trials for MAX-425 by 2029, with a projected Phase 3 milestone in 2031 and an NDA filing targeted for 2033. Specific details regarding the drug's molecular target, mechanism of action, and modality have not been publicly disclosed.

Beyond the preview

Go deeper on MAX-425.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAX-425.

Explore the full profile